Loading viewer...
investor_presentation
Format: PDF investor_presentation
Regeneron Pharmaceuticals corporate presentation from February 2024 covering pipeline updates, clinical programs, and forward-looking guidance. Includes data on marketed products including EYLEA HD, Dupixent, and Libtayo, as well as investigational candidates in oncology and other therapeutic areas. Contains non-GAAP financial measures and risk disclosures for investors.
investor_presentation
23 Pages
investor_presentation
54 Pages
Novo Banco